Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -12.50
- Piotroski Score 2.00
- Grade Buy
- Symbol (MBRX)
- Company Moleculin Biotech, Inc.
- Price $2.77
- Changes Percentage (-2.12%)
- Change -$0.06
- Day Low $2.70
- Day High $2.93
- Year High $6.24
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of drug candidates for the treatment of highly resistant tumors and viruses. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and other malignancies. It also develops WP1220, an analog of WP1066 for the topical treatment of cutaneous T-cell lymphoma; and WP1122 to treat glioblastoma multiforme and COVID-19. The company has partnership and collaboration agreements with MD Anderson; Animal Life Sciences, LLC; and WPD Pharmaceuticals Sp z.o.o. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 03/20/2025
- Fiscal Year End N/A
- Average Stock Price Target $0.00
- High Stock Price Target $0.00
- Low Stock Price Target $0.00
- Potential Upside/Downside N/A
- Consensus Rating Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$13.04
- Trailing P/E Ratio -0.33
- Forward P/E Ratio -0.33
- P/E Growth -0.33
- Net Income $-29,769,000
Income Statement
Quarterly
Annual
Latest News of MBRX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
Moleculin Biotech Inc (MBRX) Q2 2024 Earnings Call Highlights: Pivotal Phase 3 Trial for ...
The FDA meeting de-risked Annamycin's development for AML treatment, allowing higher dosing in the US. The MIRACLE Phase 3 trial has an adaptive design with a primary endpoint of complete remission....
By Yahoo! Finance | 1 month ago
